MedPath

A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome

Phase 2
Completed
Conditions
Gastrointestinal Disease
Irritable Bowel Syndrome
Colonic Diseases
Diarrhea
Interventions
Registration Number
NCT00101725
Lead Sponsor
Bausch Health Americas, Inc.
Brief Summary

This study is designed to evaluate the safety and effectiveness of an investigational drug, TRN-002 (crofelemer) to relieve the symptoms of diarrhea-predominant irritable bowel syndrome (IBS).

Detailed Description

The investigational drug is a natural product taken from a plant that grows in South America. The study medication will be administered orally twice a day. Subjects who are eligible to participate will have a 75% chance of receiving TRN-002 and a 25% chance of receiving placebo (a substance that looks similar to TRN 002 but has no activity). Subjects will not be able to remain on certain standard IBS medications (antidiarrheals) while participating in the study. The total duration is 16 weeks.

The study requires five study visits that include physical exams, ECG and blood draws for laboratory studies. A colon procedure (such as a colonoscopy or flexible sigmoidoscopy) may also be required if it has not been performed since your diagnosis and within the last 5 years. Participants will be asked to make daily entries into a touch-tone telephone diary on a daily basis.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
245
Inclusion Criteria
  • Diagnosis of diarrhea predominant Irritable Bowel Syndrome
  • Willingness to make daily calls on a touch-tone telephone
  • Willingness to have an endoscopic and/or radiologic bowel evaluation, if you have not received one since your IBS diagnosis and in the past 5 years
  • Willingness to use an approved method of birth control
Exclusion Criteria
  • Serious medical or surgical conditions
  • Gastrointestinal Cancers, Crohns Disease or Ulcerative Colitis
  • Pregnancy or breast feeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
placebocrofelemer-
500 mg crofelemercrofelemer-
250 mg crofelemercrofelemer-
125 mg crofelemercrofelemer-
Primary Outcome Measures
NameTimeMethod
To assess the safety of TRN-002 when administered twice daily for 12 consecutive weeks.
Secondary Outcome Measures
NameTimeMethod
To assess the efficacy of TRN-002 when administered twice daily for 12 consecutive weeks.

Trial Locations

Locations (29)

AGMG Clinical Research Institute

🇺🇸

Anaheim, California, United States

LeBauer Research Associates, PA

🇺🇸

Greensboro, North Carolina, United States

Clinical Research Associates

🇺🇸

Huntsville, Alabama, United States

Radiant Research Phoenix Southeast

🇺🇸

Chandler, Arizona, United States

Institute of Healthcare Assessment, Inc.

🇺🇸

San Diego, California, United States

Synergy Medical Education Alliance

🇺🇸

Saginaw, Michigan, United States

nTouch Research

🇺🇸

Peoria, Illinois, United States

Tobey Village Office Park

🇺🇸

Pittsford, New York, United States

Medoff Medical / Vital Research

🇺🇸

Greensboro, North Carolina, United States

Hanover Medical Specialists, PA

🇺🇸

Wilmington, North Carolina, United States

Consultants for Clinical Research

🇺🇸

Cincinnati, Ohio, United States

Radient Research

🇺🇸

Columbus, Ohio, United States

Jackson Clinic

🇺🇸

Jackson, Tennessee, United States

Radiant Research Dallas-North

🇺🇸

Dallas, Texas, United States

ClinSearch

🇺🇸

Chattanooga, Tennessee, United States

Memphis Gastroenterology

🇺🇸

Memphis, Tennessee, United States

Washington Gastroenterology

🇺🇸

Washington, District of Columbia, United States

Arkansas Gastroenterology

🇺🇸

North Little Rock, Arkansas, United States

Consultants for Clinical Research of South Florida

🇺🇸

Boynton Beach, Florida, United States

University Clinical Research DeLand

🇺🇸

DeLand, Florida, United States

Anderson Gastroenterology

🇺🇸

Anderson, South Carolina, United States

TriCities Medical Research

🇺🇸

Bristol, Tennessee, United States

CRC of Jakson

🇺🇸

Jackson, Mississippi, United States

Mercy Medical Group

🇺🇸

Saint Louis, Missouri, United States

Tacoma Digestive Disease Research Center

🇺🇸

Tacoma, Washington, United States

Grandview Medical Research, Inc

🇺🇸

Sellersville, Pennsylvania, United States

Piedmont Medical Research Assoc., Inc.

🇺🇸

Winston-Salem, North Carolina, United States

Community Clinical Trials

🇺🇸

Orange, California, United States

AGMG Clinical Research

🇺🇸

Orange, California, United States

© Copyright 2025. All Rights Reserved by MedPath